| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Krka was established in Slovenia in 1954 as Krka Pharmaceutical Laboratory,
and has grown to become one of the largest generic drug manufactures in
Central and Eastern Europe. This report provides an insight into the company,
reviewing its current business structure and activities.
Krka has representative offices in Albania, Azerbaijan, Belarus, Bosnia and
Herzegovina, Bulgaria, the Czech Republic, Estonia, Georgia, Hungary, India,
Kazakhstan, Kosovo, Latvia, Lithuania, Moldova, Poland, Romania, Russia,
Serbia and Montenegro, Slovakia, Ukraine and Uzbekistan. The company employed
around 5,200 people by the end of 2005.
The vast majority of the company's shareholders are Slovenian, split between
private, investment and state entities. With the acquisition of Lek by
Novartis in late 2002, Krka is now the only major Slovenian-owned
pharmaceutical company, and has consciously avoided the lure of multinational
pharmaceutical giants. Only 7.1% of Krka's shareholders were listed as foreign
investors as of 3rd February 2006.
This report provides information on the company's active product lines and
ANDA approvals, along with a review of major developments, such as M&A
activity, strategic alliances and litigation. The company's most recent
quarterly and annual financial results are illustrated with comparative
figures, charts and a detailed review of the data which allows you to track
the company's progress.
TABLE OF CONTENTS
- EXECUTIVE SUMMARY
- INTRODUCTION
- PRODUCTS
- FINANCIAL RESULTS
- Latest Yearly Results
- Financial results, 1997 - 2005 (SIT millions)
- MAJOR DEVELOPMENTS
- Facilities
- Slovenia
- Russia
- Poland
- Representative offices
- Litigation
- Simvastatin
- Atorvastatin
- Enalapril
- CONTACT DETAILS
|
